Factors Predicting the Adherence to the Therapy of Italian IBD Patients
Table 3
Oral 5-ASA compliance (high/moderate versus low) according to different confounders.
N
OR (95% CI)
aOR (95% CI)
Gender
Males
72
1
1
Females
56
0.76 (0.37–1.56)
0.77 (0.35–1.71)
Age groups
<30 years
48
1
1
31–50 years
46
2.41 (1.04-5.54)
1.79 (0.69–4.60)
>50 years
34
7.45 (2.46–22.56)
5.18 (1.47–18.2)
Type of disease
CD
50
1
1
UC
78
1.37 (0.66–2.84)
1.64 (0.70–3.83)
Disease activity
Remission
77
1
1
Active
51
1.35 (0.64–2.82)
1.62 (0.70–3.74)
Time from diagnosis
<1 year
15
1
1
1–5 years
55
2.25 (0.70–7.21)
2.20 (0.61–7.95)
>5 years
58
3.61 (1.11–11.74)
2.64 (0.71–9.81)
Concomitant drugs
No
91
1
1
Yes
37
3.51 (1.40–8.82)
2.06 (0.73–5.83)
Adjusted for sex, age groups, type of disease, disease activity, time from diagnosis, and concomitant drugs when nonstratified for. CD = Crohn’s disease; UC = ulcerative colitis.